Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Septerna, Inc. is a biotechnology company focused on advancing novel, oral small-molecule medicines targeting the entire class of G protein-coupled receptors (GPCRs). The company’s focusing the Native Complex™ Platform on tackling previously difficult-to-drug GPCR targets, and their small molecule drug discovery efforts have rapidly advanced, resulting in a pipeline of innovative programs. Septerna is building a pipeline o...
Septerna, Inc. is a biotechnology company focused on advancing novel, oral small-molecule medicines targeting the entire class of G protein-coupled receptors (GPCRs). The company’s focusing the Native Complex™ Platform on tackling previously difficult-to-drug GPCR targets, and their small molecule drug discovery efforts have rapidly advanced, resulting in a pipeline of innovative programs. Septerna is building a pipeline of GPCR-targeted, oral small-molecule drug candidates, led by its program targeting the parathyroid hormone 1 receptor (PTH1R) for the treatment of hypoparathyroidism.

List your booth number for exhibitions, ask us